Avelas Biosciences
  • About Us
    • About Us
    • Our Mission
    • Executive Team
    • Board of Directors
  • Our Science
    • Our Science
    • Intraoperative Imaging Device
    • Publications
  • Our Product
    • Pegloprastide (AVB-620)
    • Pipeline
    • Clinical Trials
    • Expanded Access
  • News
    • News
    • History
  • Contact
    • Contact
    • Careers

News

  1. Oct 18, 2021

    Avelas Makes Senior Appointments and Provides Update on Pegloprastide Phase III Clinical Program

    Read more
  2. Apr 29, 2021

    Avelas Biosciences Presents Phase 2, Period 2 Data in Virtual Poster Session at the 22nd Annual Meeting of The American Society of Breast Surgeons

    Read more
  3. Dec 14, 2020

    Avelas Receives FDA Breakthrough Therapy Designation for Pegloprastide (AVB-620) for Use During Breast Cancer Surgery

    Read more
  4. Aug 04, 2020

    Avelas Announces Top-Line Data Showing Pegloprastide (AVB-620) Can Significantly Improve Cancer Detection in Real-Time During Breast Cancer Surgery

    Read more
  5. Feb 26, 2020

    Avelas Biosciences Voted Innovator of the Year at Field Service Medical 2020

    Read more
  6. Nov 22, 2019

    Avelas Welcomes Susan Stimson to its Board of Directors

    Read more
  7. Jun 17, 2019

    Avelas Biosciences Selected as a 2019 Showcase Company by MedTech Innovator

    Read more
  8. Mar 04, 2019

    Avelas Biosciences Grows Management Team

    Read more
  9. Dec 04, 2018

    Avelas Biosciences Presents Phase II, Period 1 Data in Poster Session at San Antonio Breast Cancer Symposium

    Read more

Next Page »

  • Home
  • About Us
  • Our Science
  • Our Product
  • News
  • Contact

Copyright © Avelas Biosciences | Website by AshWebStudio